Paradigm Achieves 50% Patient Dosing in Phase 3
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The interim dataset is scheduled for independent statistical analysis, with results expected in the near future. The trial design closely mirrors a previous successful study, incorporating refinements to improve data quality and manage placebo response. This milestone is significant as it marks progress towards evaluating the efficacy and safety of the treatment being studied.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Appendix 4D and Half Year Report
- Drawdown of Tranche 3 under the Convertible Note Facility
- Published Canine Study Strengthens iPPS Phase 3 Rationale
- Oral OA Animal Therapy Progresses via AVet Deal
- December 2025 Quarterly Activities Report & Appendix 4C
Later from Paradigm Biopharmaceuticals
- Upsized $14M Placement Extends Runway Post IA
- March 2026 Quarterly Activities Report & Appendix 4C
- DSMB 20% Review Supports Phase 3, Moldova Activated
- Results of Share Purchase Plan
- PAR Completes Enrolment in Pivotal Phase 3
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals